Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 64.17K P/E - EPS this Y - Ern Qtrly Grth -
Income -11.99M Forward P/E - EPS next Y - 50D Avg Chg -99.00%
Sales 142.5k PEG - EPS past 5Y - 200D Avg Chg -99.00%
Dividend N/A Price/Book 0.00 EPS next 5Y - 52W High Chg -99.00%
Recommedations - Quick Ratio 0.01 Shares Outstanding - 52W Low Chg -
Insider Own - ROA -457.32% Shares Float - Beta -55.48
Inst Own - ROE - Shares Shorted/Prior -/1.70K Price 0.00000
Gross Margin 100.00% Profit Margin - Avg. Volume - Target Price -
Oper. Margin -756.48% Earnings Date - Volume 2,000 Change 0.00%
About AVAX TECHNOLOGIES INC

AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.